Hepatitis & IBD Drugs

Foundations and mechanisms

Viral hepatitis pharmacology: linking the viral life cycle to drug targets

Clinically important chronic viral hepatitis pharmacology centers on hepatitis B virus (HBV) and hepatitis C virus (HCV). Both cause hepatocellular injury largely through immune-mediated cytotoxicity rather than direct viral cytopathic effect. Chronic inflammation promotes fibrosis, cirrhosis, and hepatocellular carcinoma via repeated hepatocyte death, stellate-cell activation, and collagen deposition.

HBV is a partially double-stranded, enveloped DNA virus in the Hepadnaviridae family. It uniquely replicates through an RNA intermediate using a viral reverse transcriptase/DNA polymerase. After entry into hepatocytes, relaxed circular DNA is converted into covalently closed circular DNA (cccDNA) in the nucleus. cccDNA is transcriptionally stable and explains why HBV is suppressible but rarely eradicated. Drug therapy therefore aims to suppress replication and reduce progression to cirrhosis and hepatocellular carcinoma.

HCV is an enveloped, positive-sense single-stranded RNA virus in the Flaviviridae family. It replicates entirely in the cytoplasm and does not form a DNA intermediate or latent nuclear reservoir. This makes HCV potentially curable. Direct-acting antivirals achieve sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after therapy; SVR12 corresponds to cure in most patients. Modern regimens generally achieve >95% SVR in uncomplicated chronic HCV.

Virus	Core replication feature	High-yield drug targets	Clinical pharmacology principle
HBV	DNA virus using reverse transcriptase; nuclear cccDNA reservoir	HBV DNA polymerase/reverse transcriptase; host immune activation	Long-term viral suppression; cure uncommon because cccDNA persists
HCV	Positive-sense RNA virus; cytoplasmic replication	NS3/4A protease, NS5A replication complex, NS5B RNA polymerase	Finite therapy with high cure rates when multiple replication steps are blocked

Major antiviral drug mechanisms

• HBV nucleos(t)ide analogs: entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide inhibit HBV DNA polymerase/reverse transcriptase, causing chain termination after phosphorylation to active nucleotide forms. Typical adult doses include entecavir 0.5 mg orally daily, tenofovir disoproxil fumarate 300 mg orally daily, and tenofovir alafenamide 25 mg orally daily.
• Pegylated interferon-α: enhances antiviral host responses through JAK-STAT signaling, increasing transcription of interferon-stimulated genes that inhibit viral protein synthesis and RNA degradation. A classic regimen is peginterferon-α-2a 180 micrograms subcutaneously weekly, usually for 48 weeks in HBV. Toxicities reflect cytokine activation: flu-like symptoms, depression, cytopenias, and autoimmune disease exacerbation.
• HCV NS3/4A protease inhibitors: agents ending in -previr, such as glecaprevir, block cleavage of the HCV polyprotein.
• HCV NS5A inhibitors: agents ending in -asvir, such as pibrentasvir, ledipasvir, and velpatasvir, inhibit replication-complex assembly and viral assembly.
• HCV NS5B polymerase inhibitors: sofosbuvir is a nucleotide analog causing chain termination by the viral RNA-dependent RNA polymerase. Its major circulating metabolite has an approximate half-life of 27 hours.

Inflammatory bowel disease pharmacology: immune pathways and drug classes

Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn disease. Both are chronic, relapsing inflammatory disorders arising from inappropriate mucosal immune activation against intestinal microbiota in genetically susceptible hosts. Key pathways include epithelial barrier dysfunction, innate immune activation, antigen presentation, T-cell differentiation, cytokine amplification, leukocyte trafficking, and tissue injury.

Crohn disease is typically transmural, discontinuous, and can involve any GI segment from mouth to anus, classically terminal ileum and colon. Granulomas may occur. Ulcerative colitis is limited to the colon and rectum, has continuous mucosal inflammation, and increases colorectal carcinoma risk with duration and extent of disease. Pharmacology is organized around reducing mucosal inflammation, inducing remission, and maintaining remission.

IBD pathway	Mechanistic importance	Representative drugs
Prostaglandins, leukotrienes, local cytokines	Mucosal inflammatory amplification	5-aminosalicylic acid agents: mesalamine, sulfasalazine
NF-κB/AP-1 transcription and broad cytokine production	Rapid anti-inflammatory effect	Glucocorticoids: prednisone, methylprednisolone, budesonide
Purine synthesis and lymphocyte proliferation	T-cell and B-cell clonal expansion	Azathioprine, 6-mercaptopurine, methotrexate
TNF-α signaling	Macrophage activation, granuloma maintenance, endothelial activation	Infliximab, adalimumab, certolizumab, golimumab
Leukocyte adhesion and trafficking	Migration of lymphocytes into gut mucosa	Vedolizumab anti-α4β7 integrin; natalizumab anti-α4 integrin
IL-12/IL-23 and JAK-STAT signaling	Th1/Th17 differentiation and cytokine signaling	Ustekinumab anti-p40; tofacitinib JAK inhibitor; upadacitinib JAK1 inhibitor

5-ASA drugs act topically in the intestinal lumen and mucosa, decreasing prostaglandin and leukotriene synthesis and inhibiting NF-κB signaling. Sulfasalazine is cleaved by colonic bacteria into 5-ASA plus sulfapyridine; sulfapyridine causes many adverse effects, including headache, rash, reversible oligospermia, and hemolysis in G6PD deficiency. Mesalamine avoids the sulfa moiety. Typical oral mesalamine dosing is approximately 2.4–4.8 g/day for active ulcerative colitis, depending on formulation.

Glucocorticoids are effective for induction but not maintenance because chronic use causes adrenal suppression, osteoporosis, hyperglycemia, hypertension, infection risk, and Cushingoid features. Budesonide has high first-pass hepatic metabolism, reducing systemic exposure; oral ileal-release dosing is commonly 9 mg daily for mild ileocecal Crohn disease. Thiopurines require metabolism: azathioprine is converted to 6-mercaptopurine, then to active 6-thioguanine nucleotides that impair DNA synthesis. TPMT deficiency increases severe myelosuppression risk, a classic pharmacogenetic association.

Biologic agents target defined cytokine or adhesion pathways. Because TNF-α inhibitors impair granuloma maintenance, Step 1-relevant screening concepts include risk of reactivation of latent tuberculosis and HBV. Integrin blockade prevents leukocyte extravasation; natalizumab is associated with progressive multifocal leukoencephalopathy from JC virus reactivation, whereas gut-selective vedolizumab has lower systemic CNS risk.

Clinical assessment and investigations

Hepatitis: presentation, differential diagnosis, and baseline assessment

“Hepatitis” means hepatocellular inflammation, reflected biochemically by disproportionate elevation of aminotransferases. Clinically, acute hepatitis may present with fatigue, anorexia, nausea, right upper quadrant discomfort, dark urine, jaundice, and tender hepatomegaly; chronic viral hepatitis is often asymptomatic until cirrhosis. On Step 1, distinguish hepatocellular injury from cholestatic injury: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) predominate in hepatocellular disease, whereas alkaline phosphatase (ALP) and bilirubin predominate in obstruction or cholestasis.

Test	Typical adult reference range	Interpretation
ALT	~7–56 U/L	More liver-specific than AST; often highest in viral/toxic hepatitis
AST	~10–40 U/L	Also in muscle and RBCs; AST:ALT >2 suggests alcohol-associated liver disease
ALP	~40–130 U/L	Elevated in cholestasis, biliary obstruction, infiltrative disease
Total bilirubin	~0.1–1.2 mg/dL	Jaundice usually visible when >2–3 mg/dL
Albumin	~3.5–5.0 g/dL	Low in chronic synthetic dysfunction, malnutrition, nephrotic loss
INR	~0.8–1.2	Best rapid marker of hepatic synthetic failure; INR ≥1.5 plus encephalopathy defines acute liver failure

The differential diagnosis of hepatitis includes viral hepatitis A–E, alcohol, acetaminophen toxicity, ischemic hepatitis, autoimmune hepatitis, Wilson disease, hemochromatosis, nonalcoholic steatohepatitis, biliary obstruction, and drug-induced liver injury. Medication history is essential because anti-tuberculosis drugs, antiepileptics, statins, amiodarone, methotrexate, and herbal supplements can mimic viral hepatitis.

Viral hepatitis investigations relevant to pharmacology

• HAV: acute infection is diagnosed by anti-HAV IgM. HAV is usually self-limited; no chronic carrier state.
• HBV: use serology plus HBV DNA. HBsAg indicates current infection; anti-HBs indicates immunity; anti-HBc IgM indicates acute infection; anti-HBc IgG indicates prior exposure. HBeAg suggests high infectivity and active replication. Quantitative HBV DNA is reported in IU/mL.
• HCV: screen with anti-HCV antibody, then confirm active infection with HCV RNA PCR. Current AASLD/IDSA guidance recommends treatment for nearly all patients with detectable HCV RNA. Sustained virologic response, SVR12, means undetectable HCV RNA 12 weeks after therapy and is considered cure.
• HDV: requires HBV surface antigen; test anti-HDV or HDV RNA in HBsAg-positive patients with severe hepatitis or risk factors.

Before antiviral therapy, assess pregnancy status, renal function, HIV coinfection, and fibrosis stage. Noninvasive fibrosis tools are high-yield: FIB-4 = age × AST / [platelets × √ALT]; values <1.3 suggest low probability of advanced fibrosis, whereas >2.67 suggests advanced fibrosis. Cirrhosis corresponds to METAVIR F4 and changes drug choice, duration, and need for hepatocellular carcinoma surveillance. For HBV, treatment is generally considered when HBV DNA is elevated, ALT is persistently elevated, or cirrhosis is present; common thresholds are HBV DNA >20,000 IU/mL in HBeAg-positive disease or >2,000 IU/mL in HBeAg-negative disease with active inflammation.

Inflammatory bowel disease: presentation and differential diagnosis

IBD includes ulcerative colitis, a continuous mucosal disease beginning in the rectum, and Crohn disease, a transmural, skip-lesion disease that can affect any GI segment, especially terminal ileum and colon. Symptoms include chronic diarrhea, abdominal pain, weight loss, fatigue, fever, rectal bleeding, urgency, and extraintestinal manifestations such as uveitis, episcleritis, erythema nodosum, pyoderma gangrenosum, ankylosing spondylitis, and primary sclerosing cholangitis.

The differential includes infectious colitis, irritable bowel syndrome, celiac disease, ischemic colitis, microscopic colitis, colorectal cancer, diverticulitis, and medication-associated diarrhea. Before corticosteroids, thiopurines, methotrexate, or biologics, exclude infection—especially Clostridioides difficile, which can mimic an IBD flare.

IBD investigations, scoring, and thresholds

Investigation	Use	High-yield interpretation
Stool culture, ova/parasites, C. difficile NAAT/toxin	Rule out infection	Required in suspected flare, particularly before immunosuppression
Fecal calprotectin	Neutrophil-derived marker of intestinal inflammation	<50 µg/g argues against active IBD; >150–250 µg/g supports inflammatory disease
CRP, ESR	Systemic inflammation	Useful for trend; CRP may be normal in isolated UC despite active disease
CBC, iron studies, albumin	Severity and complications	Anemia, thrombocytosis, hypoalbuminemia suggest active inflammation or malnutrition
Colonoscopy with biopsy	Diagnostic gold standard	UC: continuous superficial inflammation; Crohn: skip lesions, granulomas, transmural complications
MR/CT enterography	Small bowel Crohn disease	Detects strictures, fistulas, abscesses; important before biologic escalation

Severity scores guide drug selection. The Mayo score for UC ranges 0–12 using stool frequency, rectal bleeding, endoscopy, and physician assessment; remission is typically ≤2 with no subscore >1. Acute severe UC is classically defined by Truelove-Witts criteria: ≥6 bloody stools/day plus systemic toxicity such as temperature >37.8°C, heart rate >90/min, hemoglobin <10.5 g/dL, or ESR >30 mm/hr. The Crohn Disease Activity Index classifies remission as <150 and severe disease as >450.

Pre-treatment safety investigations for IBD drugs

Because many IBD drugs suppress immunity, baseline testing is pharmacologically essential. Before anti-TNF agents, anti-integrins, anti-IL-12/23 agents, Janus kinase inhibitors, or high-dose steroids, screen for latent tuberculosis with IGRA or tuberculin skin test and chest radiograph when indicated. Check hepatitis B serologies because biologics and corticosteroids can reactivate HBV; HBsAg-positive or anti-HBc-positive patients may require antiviral prophylaxis. Before thiopurines, measure TPMT activity and consider NUDT15 genotyping; deficiency increases risk of severe myelosuppression. Obtain CBC and liver enzymes before and during azathioprine, 6-mercaptopurine, methotrexate, and JAK inhibitors. Therapeutic drug monitoring can distinguish underdosing from immunogenic failure; for example, maintenance infliximab troughs >5 µg/mL and adalimumab troughs >7.5 µg/mL are commonly targeted in active disease.

Management, pharmacology and procedures

Viral hepatitis: acute and chronic management principles

Acute hepatitis A and E are usually supportive: hydration, antiemetics, avoidance of alcohol and hepatotoxins, and monitoring for acute liver failure. Acute liver failure is suggested by INR ≥1.5 with encephalopathy in a patient without preexisting cirrhosis and requires urgent transplant-center evaluation. Hepatitis A is prevented with an inactivated vaccine; postexposure prophylaxis is vaccine within 2 weeks, with immune globulin for selected high-risk patients.

For hepatitis B, management depends on whether infection is acute or chronic and on markers of viral replication and liver injury. Chronic HBV is defined by persistence of HBsAg for >6 months. Treatment is generally considered when there is active viral replication plus hepatic inflammation, e.g. HBV DNA >2,000 IU/mL in HBeAg-negative disease or >20,000 IU/mL in HBeAg-positive disease with elevated ALT or significant fibrosis. First-line agents are high-potency nucleos(t)ide analogs with high resistance barriers.

Drug/class	Mechanism	Typical adult dose	High-yield adverse effects
Tenofovir disoproxil fumarate	Nucleotide analog; inhibits HBV DNA polymerase/reverse transcriptase	300 mg orally daily	Renal tubular toxicity, ↓ bone mineral density
Tenofovir alafenamide	Prodrug with higher intracellular delivery and lower plasma tenofovir	25 mg orally daily	Less renal/bone toxicity than TDF
Entecavir	Guanosine analog; blocks priming, reverse transcription, and DNA synthesis	0.5 mg orally daily; 1 mg if lamivudine-resistant	Lactic acidosis rare; dose-adjust in renal disease
Pegylated interferon-α	Enhances antiviral immune response; ↑ MHC class I, activates NK cells	Peg-IFN-α2a 180 μg weekly for 48 weeks	Flu-like symptoms, depression, cytopenias, autoimmune thyroiditis

Pregnant patients with high HBV DNA, typically >200,000 IU/mL, may receive tenofovir in the third trimester to reduce vertical transmission. Newborns of HBsAg-positive mothers receive HBV vaccine plus HBIG within 12 hours of birth.

Hepatitis C is now treated with direct-acting antivirals targeting viral proteins. Modern regimens achieve sustained virologic response at 12 weeks after therapy (SVR12, functional cure) in >95% of adherent patients. Examples include sofosbuvir/velpatasvir 400/100 mg daily for 12 weeks or glecaprevir/pibrentasvir 300/120 mg daily for 8 weeks in many noncirrhotic patients. Sofosbuvir inhibits the NS5B RNA-dependent RNA polymerase; velpatasvir and pibrentasvir inhibit NS5A replication complex; glecaprevir inhibits NS3/4A protease. Screen for HBV before HCV therapy because DAA-associated immune shifts can cause HBV reactivation.

Inflammatory bowel disease: step-up and treat-to-target pharmacology

IBD therapy aims to induce remission, maintain steroid-free remission, prevent complications, and reduce colorectal cancer risk. Ulcerative colitis is continuous mucosal inflammation beginning in the rectum; Crohn disease is transmural, skip-lesion inflammation that can involve any GI segment. Severity is assessed clinically and by biomarkers such as CRP and fecal calprotectin; endoscopy confirms mucosal healing.

Therapy	Mechanism and use	Key toxicities/monitoring
5-aminosalicylic acid Mesalamine 2.4–4.8 g/day orally; rectal 1 g nightly	Topical anti-inflammatory effect in colonic mucosa; inhibits prostaglandin/leukotriene synthesis and NF-κB signaling. Best for mild–moderate UC; limited Crohn benefit.	Headache, nausea, interstitial nephritis; monitor creatinine.
Sulfasalazine	5-ASA linked to sulfapyridine by azo bond cleaved by colonic bacteria.	Folate deficiency, reversible oligospermia, hemolysis in G6PD deficiency, sulfa allergy.
Corticosteroids Prednisone 40–60 mg/day; budesonide 9 mg/day	Induction only; bind cytosolic glucocorticoid receptor → altered transcription, ↓ IL-1, IL-2, TNF-α, COX-2.	Cushingoid changes, hyperglycemia, osteoporosis, infection, adrenal suppression; not for maintenance.
Azathioprine/6-mercaptopurine	Purine analogs; inhibit lymphocyte proliferation. Maintenance and steroid-sparing, delayed onset 8–12 weeks.	Check TPMT or NUDT15; myelosuppression, hepatotoxicity, pancreatitis, lymphoma risk.
Methotrexate 15–25 mg weekly	Dihydrofolate reductase inhibition; ↑ adenosine anti-inflammatory signaling. Used more in Crohn maintenance.	Hepatotoxicity, marrow suppression, mucositis, teratogenicity; give folic acid.
Anti-TNF agents Infliximab 5 mg/kg IV at weeks 0, 2, 6 then q8wk; adalimumab SC	Neutralize TNF-α; induce apoptosis of activated T cells/macrophages. Moderate–severe UC or Crohn; fistulizing Crohn.	Screen for TB and HBV; infusion reactions, serious infections, demyelination, worsening heart failure. SONIC trial showed infliximab + azathioprine superior to either alone in Crohn remission.
Vedolizumab	Anti-α4β7 integrin; blocks gut-homing lymphocyte adhesion to MAdCAM-1.	Gut-selective; lower systemic immunosuppression. GEMINI trials supported UC and Crohn efficacy.
Ustekinumab	Anti-p40 monoclonal antibody blocks IL-12 and IL-23 signaling, reducing Th1/Th17 responses.	Infections; generally favorable safety profile.
JAK inhibitors Tofacitinib 10 mg twice daily induction in UC	Inhibit intracellular cytokine signaling via JAK-STAT pathways.	Herpes zoster, lipid elevation, thrombosis warning; avoid in pregnancy.

Procedures, complications, and follow-up

Colonoscopy with biopsy is diagnostic and used for dysplasia surveillance. In extensive UC or Crohn colitis, surveillance typically begins 8 years after symptom onset and repeats every 1–3 years depending on risk factors. Toxic megacolon is colonic dilation >6 cm with systemic toxicity; precipitating antidiarrheals or opioids must be stopped, and urgent medical-surgical evaluation is required. UC can be cured surgically by total proctocolectomy, often with ileal pouch–anal anastomosis; Crohn is not cured by resection because recurrence is common. Vaccination, TB/HBV screening before biologics, osteoporosis prevention during steroid exposure, and routine monitoring of CBC, liver enzymes, renal function, and inflammatory markers are essential longitudinal care principles.

Exam controversies and advanced synthesis

Antiviral hepatitis therapy: what Step 1 expects versus what modern guidelines emphasize

For USMLE Step 1, know the mechanistic classes and signature toxicities; for synthesis, recognize that modern hepatitis treatment is driven by viral replication markers, fibrosis stage, and resistance barriers. In chronic hepatitis B, the key laboratory distinction is between HBsAg persistence >6 months and active viral replication, assessed by HBV DNA, HBeAg, and ALT. Current AASLD-style thresholds commonly treat immune-active disease when ALT is elevated and HBV DNA is high: approximately >20,000 IU/mL in HBeAg-positive disease or >2,000 IU/mL in HBeAg-negative disease, especially with fibrosis. “Normal” ALT cutoffs used in HBV guidance are lower than many laboratory reference ranges: about ≤35 U/L in men and ≤25 U/L in women.

Drug/class	High-yield mechanism	Typical adult dose	Major pitfall
Tenofovir disoproxil fumarate	Nucleotide reverse transcriptase inhibitor; chain termination of HBV DNA	300 mg PO daily	Renal tubular toxicity, ↓ bone mineral density
Tenofovir alafenamide	Same active metabolite; lower plasma tenofovir exposure	25 mg PO daily	Less renal/bone toxicity; still monitor renal function
Entecavir	Guanosine analog inhibiting HBV polymerase	0.5 mg PO daily if nucleoside-naïve	Low resistance barrier if prior lamivudine resistance
Pegylated interferon-α	Enhances antiviral immune signaling via JAK-STAT pathways	Weekly injection, often 48 weeks	Flu-like symptoms, depression, cytopenias, autoimmune disease flare

A frequent examination trap is HBV reactivation. Anti-TNF drugs, high-dose glucocorticoids, anthracyclines, JAK inhibitors, and especially anti-CD20 therapy can permit rapid HBV replication. Therefore, before biologic or potent immunosuppressive therapy, screen with HBsAg, anti-HBs, and anti-HBc. HBsAg-positive patients usually require antiviral prophylaxis with high-barrier agents such as tenofovir or entecavir.

Hepatitis C pharmacology has shifted from interferon-ribavirin to direct-acting antivirals. Trials of combinations such as sofosbuvir-based regimens and glecaprevir/pibrentasvir consistently show sustained virologic response at 12 weeks after therapy (SVR12) >95% in many uncomplicated populations. SVR12 is considered virologic cure. Mechanistically, DAAs target the HCV polyprotein processing/replication complex: NS3/4A protease inhibitors end in -previr, NS5A inhibitors end in -asvir, and NS5B polymerase inhibitors end in -buvir. Sofosbuvir is classically 400 mg PO daily. Glecaprevir/pibrentasvir is 300/120 mg PO daily with food, often for 8 weeks in treatment-naïve patients without cirrhosis. Ribavirin remains testable because it causes hemolytic anemia and is strongly teratogenic; pregnancy should be avoided during therapy and for 6 months afterward.

IBD drugs: trials, treatment targets, and common exam pitfalls

Inflammatory bowel disease treatment is often tested through mechanisms rather than full clinical algorithms. Still, modern practice uses a treat-to-target framework: improve symptoms, normalize biomarkers such as CRP and fecal calprotectin, and achieve endoscopic mucosal healing. STRIDE-II targets often use fecal calprotectin roughly <150–250 μg/g as a noninvasive marker of reduced intestinal inflammation.

IBD drug	Mechanism	Typical dosing anchor	High-yield toxicity/pitfall
Mesalamine, sulfasalazine	Topical anti-inflammatory effect; ↓ prostaglandins/leukotrienes via COX/LOX modulation	Mesalamine 2.4–4.8 g/day PO; rectal forms for distal UC	Best for ulcerative colitis; limited value in Crohn disease
Prednisone; IV methylprednisolone	Glucocorticoid receptor activation; ↓ NF-κB cytokine transcription	Prednisone 40–60 mg/day; methylprednisolone 60 mg/day IV in severe UC	Induction only; not maintenance
Azathioprine/6-MP	Purine synthesis inhibition; impairs lymphocyte proliferation	Azathioprine 2–2.5 mg/kg/day	Check TPMT/NUDT15; myelosuppression, hepatotoxicity, pancreatitis
Infliximab	Chimeric monoclonal anti-TNF-α antibody	5 mg/kg IV at weeks 0, 2, 6, then q8 weeks	TB/HBV reactivation, infusion reactions, demyelination, worsening heart failure
Vedolizumab	Anti-α4β7 integrin; blocks gut lymphocyte homing to MAdCAM-1	300 mg IV at weeks 0, 2, 6, then q8 weeks	Gut-selective; less systemic immunosuppression than anti-TNF
Ustekinumab	Anti-p40 subunit shared by IL-12 and IL-23	Weight-based IV induction, then 90 mg SC q8 weeks	Infection risk; also used in psoriasis
Tofacitinib	JAK inhibitor; blocks cytokine signaling downstream of multiple receptors	10 mg PO BID induction, then 5 mg BID maintenance in UC	Herpes zoster, thrombosis, MACE boxed warnings, lipid elevation

Several landmark trials illustrate concepts that may appear in vignettes. The SONIC trial in Crohn disease showed higher corticosteroid-free remission with infliximab plus azathioprine than with either alone: approximately 56.8% versus 44.4% with infliximab and 30.0% with azathioprine at week 26. The Step 1 lesson is not to memorize gastroenterology algorithms, but to understand why combination therapy can reduce anti-drug antibody formation against a biologic. Anti-drug antibodies lower trough levels and cause loss of response or infusion reactions; maintenance infliximab trough targets are often roughly >3–7 μg/mL, depending on disease severity and assay.

Another common pitfall is confusing ulcerative colitis severity scoring with drug mechanism. Acute severe ulcerative colitis is classically suggested by ≥6 bloody stools/day plus systemic toxicity such as fever, tachycardia, anemia, or elevated ESR/CRP. Initial therapy is IV glucocorticoids; steroid-refractory disease may use rescue infliximab or cyclosporine, but Step 1 emphasis is on toxicity: cyclosporine inhibits calcineurin, causing nephrotoxicity, hypertension, neurotoxicity, and gingival hyperplasia.

Finally, biologic safety questions often hinge on prevention. Before anti-TNF, anti-integrin, anti-IL, or JAK inhibitor therapy, assess latent tuberculosis, hepatitis B serologies, vaccination status, and avoid live vaccines during significant immunosuppression. This integrates microbiology, immunology, and pharmacology: blocking cytokines that drive granuloma maintenance, especially TNF-α, can convert contained latent infection into disseminated disease.